Aigen Investment Management LP Takes Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Aigen Investment Management LP bought a new stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 10,994 shares of the specialty pharmaceutical company’s stock, valued at approximately $338,000.

Several other institutional investors have also made changes to their positions in the stock. Pacer Advisors Inc. grew its position in Collegium Pharmaceutical by 68.4% during the 4th quarter. Pacer Advisors Inc. now owns 2,174,718 shares of the specialty pharmaceutical company’s stock worth $66,938,000 after acquiring an additional 883,380 shares during the last quarter. Assenagon Asset Management S.A. grew its stake in shares of Collegium Pharmaceutical by 178.1% in the 3rd quarter. Assenagon Asset Management S.A. now owns 425,630 shares of the specialty pharmaceutical company’s stock valued at $9,513,000 after buying an additional 272,565 shares during the period. New York State Common Retirement Fund grew its position in Collegium Pharmaceutical by 1,475.5% in the 4th quarter. New York State Common Retirement Fund now owns 201,112 shares of the specialty pharmaceutical company’s stock valued at $6,190,000 after purchasing an additional 188,347 shares during the period. Qube Research & Technologies Ltd increased its holdings in Collegium Pharmaceutical by 713.3% during the 3rd quarter. Qube Research & Technologies Ltd now owns 127,010 shares of the specialty pharmaceutical company’s stock worth $2,839,000 after purchasing an additional 111,394 shares in the last quarter. Finally, Federated Hermes Inc. lifted its position in shares of Collegium Pharmaceutical by 76.0% during the fourth quarter. Federated Hermes Inc. now owns 212,768 shares of the specialty pharmaceutical company’s stock valued at $6,549,000 after purchasing an additional 91,911 shares in the last quarter.

Analyst Upgrades and Downgrades

COLL has been the subject of a number of recent research reports. Needham & Company LLC downgraded Collegium Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Friday, May 10th. Piper Sandler downgraded shares of Collegium Pharmaceutical from an “overweight” rating to a “neutral” rating and set a $39.00 target price on the stock. in a research note on Friday, May 10th. StockNews.com cut Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, May 1st. Finally, Truist Financial raised their price objective on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a report on Monday, February 26th. Four analysts have rated the stock with a hold rating and two have given a buy rating to the company. According to MarketBeat, Collegium Pharmaceutical currently has a consensus rating of “Hold” and an average target price of $39.00.

Insider Transactions at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, Director Garen G. Bohlin sold 28,985 shares of the company’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $32.30, for a total transaction of $936,215.50. Following the transaction, the director now owns 44,775 shares in the company, valued at approximately $1,446,232.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 3.98% of the company’s stock.

Collegium Pharmaceutical Stock Up 1.3 %

Shares of Collegium Pharmaceutical stock traded up $0.43 during midday trading on Friday, hitting $34.25. The company had a trading volume of 320,990 shares, compared to its average volume of 506,732. Collegium Pharmaceutical, Inc. has a 52-week low of $20.83 and a 52-week high of $40.95. The company has a debt-to-equity ratio of 1.98, a quick ratio of 1.14 and a current ratio of 1.21. The stock has a market capitalization of $1.12 billion, a P/E ratio of 14.27 and a beta of 1.06. The company has a 50 day moving average of $36.74 and a 200 day moving average of $33.11.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.20 by $0.25. The firm had revenue of $149.75 million for the quarter, compared to the consensus estimate of $147.66 million. Collegium Pharmaceutical had a net margin of 16.46% and a return on equity of 104.98%. On average, equities analysts predict that Collegium Pharmaceutical, Inc. will post 5.63 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.